Your browser is no longer supported. Please, upgrade your browser.
Settings
JNJ Johnson & Johnson daily Stock Chart
JNJ [NYSE]
Johnson & Johnson
IndexDJIA S&P500 P/E22.96 EPS (ttm)5.95 Insider Own0.02% Shs Outstand2.71B Perf Week3.57%
Market Cap369.64B Forward P/E17.82 EPS next Y7.67 Insider Trans-20.36% Shs Float2.69B Perf Month1.75%
Income16.51B PEG3.59 EPS next Q1.80 Inst Own67.80% Short Float0.59% Perf Quarter12.06%
Sales72.17B P/S5.12 EPS this Y8.30% Inst Trans-0.07% Short Ratio2.83 Perf Half Y19.59%
Book/sh25.99 P/B5.25 EPS next Y7.91% ROA11.70% Target Price133.39 Perf Year9.13%
Cash/sh14.54 P/C9.40 EPS next 5Y6.40% ROE23.10% 52W Range109.32 - 137.00 Perf YTD18.54%
Dividend3.36 P/FCF43.15 EPS past 5Y11.20% ROI17.00% 52W High-0.31% Beta0.77
Dividend %2.46% Quick Ratio2.20 Sales past 5Y2.00% Gross Margin69.90% 52W Low24.93% ATR1.54
Employees126400 Current Ratio2.50 Sales Q/Q1.60% Oper. Margin27.80% RSI (14)68.75 Volatility1.31% 1.10%
OptionableYes Debt/Eq0.46 EPS Q/Q1.00% Profit Margin22.90% Rel Volume1.05 Prev Close135.21
ShortableYes LT Debt/Eq0.38 EarningsJul 18 BMO Payout52.80% Avg Volume5.61M Price136.57
Recom2.50 SMA202.29% SMA504.48% SMA20012.34% Volume6,088,612 Change1.01%
Jul-20-17Resumed Credit Suisse Outperform $148
Jul-05-17Reiterated Morgan Stanley Overweight $135 → $140
May-18-17Reiterated Stifel Hold $124 → $128
May-15-17Upgrade JP Morgan Neutral → Overweight
Jan-26-17Downgrade Wells Fargo Outperform → Market Perform
Jan-25-17Reiterated RBC Capital Mkts Outperform $133 → $128
Oct-19-16Reiterated UBS Buy $137 → $144
Jul-21-16Reiterated Deutsche Bank Hold $125 → $142
Jul-20-16Reiterated UBS Buy $126 → $137
Jul-20-16Reiterated RBC Capital Mkts Outperform $125 → $133
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Apr-15-16Reiterated RBC Capital Mkts Outperform $114 → $122
Mar-14-16Upgrade Goldman Sell → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Jul-20-17 06:14PM  Why 3M Hit an All-Time High GuruFocus.com
05:55PM  Growth Investing in a Sophisticated Market GuruFocus.com
05:33PM  Rule Breaker Mailbag: Is Corporate Leadership Really as Important as the Fool Says? Motley Fool
04:03PM  Abbott Zeros In On A 2-Year High After Topping Q2 Sales, Profits Investor's Business Daily
02:51PM  Rats! Chipotle Mexican Grill, Inc. (CMG) Stock Is Falling Apart! InvestorPlace
12:36PM  Q2 Earnings Scorecard and Stock Reports for JNJ, Coke & Honeywell Zacks
11:40AM  Johnson & Johnson Shares Strong Since Actelion Acquisition, But Potential For Upside Remains Benzinga
10:39AM  Stryker Expands Its Interventional Spine Segment Market Realist
09:35AM  Pfizer: We Still Like You But Barrons.com
08:59AM  Microsoft Corporation (MSFT) Stock Is Pricey, But Poised to Pounce InvestorPlace
07:45AM  Earnings Review and Free Research Report: Johnson & Johnsons Adjusted EPS Grew 5.2%; Exceeded Expectations Accesswire
Jul-19-17 04:22PM  Sarepta Rockets On Consensus-Crushing Sales, Narrowing Losses Investor's Business Daily
03:50PM  Why You Should Wait Before Buying Into an IPO Motley Fool
02:48PM  5 Off-the-Radar Numbers to Take Note of in Johnson & Johnson's Second-Quarter Report Motley Fool
01:50PM  Edited Transcript of JNJ earnings conference call or presentation 18-Jul-17 12:30pm GMT Thomson Reuters StreetEvents
12:52PM  Yacktman Focused Fund Divests Unilever in 2nd Quarter GuruFocus.com
11:55AM  J&J Brightens Outlook: Healthcare ETFs in Focus Zacks
10:33AM  Company News for July 19, 2017 Zacks
08:02AM  3 Stocks to Supplement Your Social Security Income Motley Fool
06:00AM  10 Companies That Apple Doesn't Have Enough Cash to Buy Motley Fool
12:47AM  [$$] Johnson & Johnson Raises Guidance The Wall Street Journal
Jul-18-17 10:02PM  Johnson & Johnson tops 2Q profit forecasts Associated Press
06:53PM  Cramer: Washington at fault for market's pessimism CNBC Videos
06:44PM  Cramer blames Washington for the stock market's pessimism CNBC Videos
04:52PM  US STOCKS-Nasdaq hits record on Netflix boost; Dow dragged by Goldman Reuters
04:41PM  This Drug Bellwether's Sales Miss Actually Bodes Well For The Sector Investor's Business Daily
04:16PM  These 2 Drug Giants In Buy Range Just Beat Earnings Views Investor's Business Daily
04:13PM  Johnson & Johnson Is Ready to Break Out in a Big Way Despite Lackluster Sales Growth TheStreet.com
02:44PM  J&J sees sales growth in near-term; raises 2017 profit forecast Reuters
02:31PM  UPDATE 4-J&J sees sales growth in near-term; raises 2017 profit forecast Reuters
01:41PM  Johnson & Johnson Signals It Could Make Additional Divestitures TheStreet.com
01:26PM  Johnson & Johnson ups expectations Associated Press
01:23PM  Johnson & Johnson's Growth Prognosis Is Cloudy Investopedia
11:44AM  [$$] Johnson & Johnson Raises Guidance The Wall Street Journal
11:34AM  Johnson & Johnson Raises Yearly Sales, Profit Outlook TheStreet.com
11:33AM  Jim Cramer on Netflix, Bank of America, Goldman Sachs, UnitedHealth, Johnson & Johnson, Advanced Micro Devices, IBM and Nvidia TheStreet.com
11:18AM  Hold Off on Buying This Great American Company, Jim Cramer Explains TheStreet.com
10:57AM  Johnson & Johnson (JNJ) Reports Q2 Earnings Beat InvestorPlace
10:02AM  Wall Street Banks And Household Brands Report Earnings Zacks
09:58AM  Johnson & Johnson Shares Slip Following Mixed Earnings 24/7 Wall St.
09:49AM  J&J (JNJ) Beats on Q2 Earnings, Lags Sales, Ups 2017 View Zacks
09:43AM  Despite Falling Drug Sales, Johnson & Johnson Remains Optimistic Motley Fool
09:41AM  Q2 Earnings Reports Hit the Tape: GS, BAC, JNJ, LMT & UNH Zacks
09:27AM  Stocks to Watch: Netflix, Bank of America, Goldman, J&J, Harley-Davidson The Wall Street Journal
09:23AM  Cramer's Mad Dash: Johnson & Johnson ups guidance CNBC Videos
08:22AM  5 Big Pharma Stocks With the Best Drug Pipelines Motley Fool
08:13AM  J&J (JNJ) Beats on Q2 Earnings, Ups 2017 EPS & Sales View Zacks
08:01AM  Early movers: HOG, UNH, BAC, JNJ, CMA, NFLX, TSLA & more CNBC
07:58AM  Big Pharma Share Buybacks Not Impacting R&D Budgets Forbes
07:19AM  Johnson & Johnson reports second-quarter earnings beat CNBC Videos
07:08AM  Johnson & Johnson reports mixed second quarter, revenues ... CNBC Videos
06:59AM  Johnson & Johnson tops profit estimates, but sales fall short MarketWatch
06:40AM  Johnson & Johnson Reports 2017 Second-Quarter Results: PR Newswire
06:30AM  3 Healthcare Stocks for Ambitious Investors Motley Fool
03:51AM  Johnson & Johnson earnings: A challenging second quarter poised for a turnaround MarketWatch
12:01AM  Asian stocks sink as US politics weigh on market outlook Associated Press
Jul-17-17 07:01PM  Cramer: This Week of Earnings Will Tell Us Just About Everything We Need to Know TheStreet.com
06:39PM  Cramer explains why CEO departures are not always bad for... CNBC Videos
06:35PM  Cramer's game plan: A make-or-break week for every key se... CNBC Videos
06:16PM  Cramer's game plan: A make-or-break week for every key sector CNBC
06:10PM  Make-or-break week for every key sector CNBC Videos
04:43PM  4 Things That Matter When Johnson & Johnson Reports Its Second-Quarter Results Motley Fool
04:16PM  Lockheed, Goldman Begin Fast And Furious Earnings: Investing Action Plan Investor's Business Daily
02:59PM  Earnings Roundup: JNJ, IBM, And LMT Report Q2 Results Tomorrow Benzinga
01:54PM  Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says TheStreet.com
01:21PM  Trian's Peltz seeks a seat on board at Procter & Gamble Associated Press
12:57PM  US STOCKS-Wall St slightly up as earnings season picks up pace Reuters
11:26AM  How Bristol-Meyers Squibb Has Benefited from Intangible Assets Market Realist
11:07AM  US STOCKS-Wall St holds steady as investors await big earnings Reuters
10:39AM  Analysts Latest Recommendations for Johnson & Johnson Market Realist
10:33AM  Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2017 PR Newswire
09:26AM  4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings Zacks
09:07AM  Johnson & Johnsons 2Q17 Estimates: Medical Devices Market Realist
07:38AM  Abbott Laboratories Dividend Growth and Payout Potential in 2017 Market Realist
07:38AM  Johnson & Johnsons 2Q17 Estimates: Consumer Healthcare Market Realist
07:35AM  4 Warren Buffett Stocks to Buy in July Motley Fool
05:57AM  Biotech Scoop: Valeant Pharmaceuticals Intl Inc (VRX), Teva Pharmaceutical (TEVA), and Kite Pharma (KITE) SmarterAnalyst
Jul-16-17 07:22AM  3 Warren Buffett Stocks You Can Buy and Hold for Decades Motley Fool
Jul-15-17 10:25AM  Goldman Sachs, IBM and More Dow Stocks Reporting Next Week 24/7 Wall St.
07:22AM  3 Dividend Stocks Ideal for Your Golden Years Motley Fool
Jul-14-17 05:32PM  Forget Costco Wholesale Corp: Here Are 3 Better Dividend Stocks Motley Fool
04:53PM  Netflix, Microsoft, GE, Lockheed To Amp Up Earnings: Investing Action Plan Investor's Business Daily
03:18PM  How a Mongolian Organic Skincare Entrepreneur Overcame the Odds Fortune
02:35PM  Johnson & Johnson's Near Term Growth Likely To Remain Subdued Forbes
02:21PM  Surprise: Those great companies generally turn out to be meh ... or duds MarketWatch
02:07PM  AbbVie Inc (ABBV) Stock Isnt Done Charting New Highs Yet InvestorPlace
01:05PM  Johnson & Johnsons 2Q17 Estimates: Pharmaceuticals Market Realist
12:24PM  Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment TheStreet.com
11:59AM  Kevin O'Leary: Own big, quality names CNBC Videos
11:35AM  Johnson & Johnsons 2Q17 Revenue Estimates: Expect Growth! Market Realist
10:22AM  J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab Zacks
09:44AM  What to Expect from Johnson & Johnsons 2Q17 Earnings Market Realist
09:35AM  J&J Psoriasis Drug Approval 'Another Negative' For Valeant Barrons.com
09:01AM  Why Healthcare Funds Are Not Sickened By GOP Bid To Kill Obamacare Forbes
07:28AM  Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co. Zacks
07:01AM  Abbott Partners Bigfoot Biomedical to Expand in Diabetics Zacks
Jul-13-17 06:08PM  FDA OKs new Johnson & Johnson treatment for psoriasis Associated Press
04:20PM  Johnson & Johnson Looks Sick TheStreet.com
01:24PM  Better Dividend Aristocrat: Johnson & Johnson or Medtronic? GuruFocus.com
10:30AM  Amgen's Myeloma Drug Improves Overall Survival in Phase III Zacks
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising brand adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Duato JoaquinExec VP, WW Chair, PharmaMar 03Option Exercise59.7650,0002,987,780118,536Mar 07 04:21 PM
Duato JoaquinExec VP, WW Chair, PharmaMar 03Sale123.6250,0006,181,14068,536Mar 07 04:21 PM
Kapusta Ronald AController, CAOFeb 28Option Exercise72.5414,5431,054,94944,507Mar 02 05:50 PM
Kapusta Ronald AController, CAOFeb 28Sale122.2614,5431,777,95429,964Mar 02 05:50 PM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 28Sale122.2116,2991,991,94343,630Mar 02 05:16 PM
Stoffels PaulusExec VP, Chief Scientific OffFeb 15Sale117.2922,0002,580,274127,650Feb 16 06:53 PM
Caruso Dominic JExec VP, Finance; CFOFeb 13Option Exercise0.0026,9470150,700Feb 15 10:00 PM
Kapusta Ronald AController, CAOFeb 13Option Exercise0.002,148030,052Feb 16 06:01 AM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 13Option Exercise0.0015,532063,405Feb 16 06:01 AM
Duato JoaquinExec VP, WW Chair, PharmaFeb 13Option Exercise0.0022,298075,814Feb 16 06:01 AM
Fasolo PeterExec VP, Chief HR OfficerFeb 13Option Exercise0.0015,598068,899Feb 16 06:01 AM
Gorsky AlexChairman, CEOFeb 13Option Exercise0.0084,2990280,617Feb 16 06:01 AM
PETERSON SANDRA EExec VP, Group WW ChairmanFeb 13Option Exercise0.0027,667069,436Feb 16 06:01 AM
Stoffels PaulusExec VP, Chief Scientific OffFeb 13Option Exercise0.0026,4470156,125Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 13Option Exercise0.0014,6000114,866Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 01Option Exercise65.6227,7351,819,971119,190Feb 03 12:05 PM
Ullmann Michael HExec VP, General CounselFeb 01Sale112.8821,7352,453,44297,455Feb 03 12:05 PM
PRINCE CHARLESDirectorOct 21Buy114.1187599,84626,520Oct 25 01:52 PM
JOHNSON & JOHNSON10% OwnerAug 16Buy12.00583,3336,999,9962,449,183Aug 18 05:11 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Option Exercise65.6241,1462,700,001157,819Jul 28 04:34 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Sale125.0141,1465,143,810116,673Jul 28 04:34 PM
Kapusta Ronald AController, CAOJul 22Sale125.012,935366,89625,725Jul 25 03:18 PM